Home Study CME Enrollment Form/QuestionnaireProgram Description and Objectives: The Journal of Urology® Home Study Course is a comprehensive learning activity developed by a team ofeducators, academicians and clinicians. After completing the program, urologists will be able to demonstrate an increase in or affirmation of theirknowledge of clinical medicine. They will also be able to evaluate the appropriateness of clinical data and apply it to their practice and to theprovision of improved patient care.

Program Format: Two volumes of The Journal of Urology® are published annually. Each volume is comprised of 6 issues. Five clinically relevantarticles are selected by the editor to be read in each issue of The Journal. Answer 5 related questions on the examination and either mail the paperform in the provided envelope or submit online. Completion of each test and a score of 80% or more qualify for 2 hours of Category 1 CME Credit toa maximum of 24 credits annually.

Program Enrollment: There are 3 convenient ways to enroll in The Journal of Urology� Home Study Course. 1) Complete the form below andreturn by MAIL with payment of $60.00 for 2 volumes (24 credits) enrollment. Please designate your choice of paper examination forms or onlineexaminations. If you choose paper, answer sheets and pre-addressed envelopes will be sent to you. 2) Complete the form below and return by FAX to410-689-3904 with payment of $60.00 for two volumes (24 credits) enrollment. Please designate your choice of paper examination forms or onlineexaminations. If you choose paper, answer sheets and pre-addressed envelopes will be sent to you. 3) Go online to www.auanet.org. Choose Catalog/Products. On the next screen select Home Study/CME and click on Print from the choices offered. With your AUA identification number,password and credit card information, you may purchase 6-month volumes (12 credits) and designate your choice of paper or onlineexaminations.

Accreditation: The American Urological Association Education and Research, Inc. is accredited by the Accreditation Council for ContinuingMedical Education (ACCME) to provide continuing medical education (CME) for physicians. The American Urological Association Education andResearch, Inc. takes responsibility for the content, quality and scientific integrity of this CME activity.

CME Credit: The American Urological Association Education and Research, Inc. designates this Journal educational activity for a maximum of 24category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent on thiseducational activity.

See page 403 for questionnaire

The Journal of Urology® Home Study Program Registration Form

Volume #

$60 subscription cost covers two consecutive volumes beginning with Vol. 171Volume # 24 Category 1 credit hours

Name:

Address:

City: State: Zip:

Daytime Phone: ( )

( ) Check enclosed for $ payable to: American Urological Association Education and Research, Inc.®

Charge to ( ) VISA ( ) MasterCard ( ) AMEX

Card Number: Exp. Date:

Signature:

Please mail or fax registration form to: American Urological Association Education and Research, Inc.®

1000 Corporate Blvd.Linthicum, MD 21090Telephone: 1-410-689-3934Fax: 1-410-689-3937

402

CME QUESTIONS FOR JULY 2005 ISSUE OFTHE JOURNAL OF UROLOGY

1. A SURVEY OF PATIENTS WITH INFLATABLE PENILE PROSTHESES FOR PATIENT SATISFACTION (vol. 174,pp. 253–257)

In prior studies on satisfaction with inflatable penile prostheses, a 2-point scale—satisfied/unsatisfied—showedsatisfaction rates of approximately 88% to 91%. This study used a 3-point satisfaction scale—satisfied/neither satisfiednor unsatisfied/unsatisfied—with what percent of patients being satisfied?

a) 35%b) 43%c) 61%d) 69%e) 82%

2. INTERMEDIATE-TERM BIOCHEMICAL PROGRESSION RATES AFTER RADICAL PROSTATECTOMY ANDRADIOTHERAPY IN PATIENTS WITH SCREEN DETECTED PROSTATE CANCER (vol. 174, pp. 126–130)

Biochemical progression in patients treated with radiotherapy is currently defined by the American Society forTherapeutic Radiology and Oncology as 3:

a) increases in serum prostate specific antigen (PSA) after reaching a level of 4.0 ng/ml or moreb) increases in serum PSA of 0.2 ng/ml or morec) consecutive increases in serum PSA at intervals of 3 or more monthsd) consecutive increases in serum PSA at intervals of 6 or more monthse) increases in serum PSA at intervals of 3 or more months

3. LIVING UNRELATED DONOR RENAL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE (vol. 174, pp. 223–225)

Compared with living, genetically related donor renal transplantation, kidney transplantation from living, genetically unrelateddonors is:

a) unacceptable because of inferior graft survivalb) 5 times more common now than a decade agoc) unacceptable because the donors receive payment for their kidneysd) unacceptable because of inferior kidney transplant functione) unnecessary because of the abundance of deceased donor kidneys for transplantation

4. NEOADJUVANT MVAC IN HISTOLOGICALLY PROVEN LYMPH NODE POSITIVE BLADDER CANCER (vol. 174,pp. 80–85)

The best predictor of good prognosis after neoadjuvant MVAC and cystectomy in lymph node positive bladder cancer is:

a) complete response to MVAC in lymph nodes, independent of response of the primary tumorb) complete and partial response in lymph nodes, independent of response of the primary tumorc) complete response in lymph nodes and primary tumord) complete and partial response in lymph nodes and primary tumore) complete surgical removal of tumor positive tissue after chemotherapy

5. BACILLUS CALMETTE-GUERIN VERSUS CHEMOTHERAPY IN THE INTRAVESICAL TREATMENT OFPATIENTS WITH CARCINOMA IN SITU OF THE BLADDER: A META-ANALYSIS OF THE PUBLISHEDRESULTS OF RANDOMIZED CLINICAL TRIALS (vol. 174, pp. 86–92)

In the treatment of carcinoma in situ of the bladder, intravesical bacillus Calmette-Guerin is superior to intravesicalchemotherapy with respect to:

a) the complete response rateb) the recurrence rate in complete respondersc) the long-term disease-free (no evidence of disease) rated) a and c onlye) a, b and c

The Journal of Urology®

Volume 174, Number 1, July 2005

403